Remove Engineering Remove Marketing Remove Organic Chemistry
article thumbnail

Developing the next generation of antibody drug conjugates

Drug Target Review

Despite excellent pharmacokinetic and stable antibody-linker connections, such ADCs have yet to receive market approval. Site-specific conjugations often necessitate the re-engineering of antibody sequencing to introduce amino acid with a reactive functional group. This approach offers the advantage of using chemical modification.

article thumbnail

Women in Stem with Dr Emily Leproust

Drug Target Review

I started my journey in chemistry – first as an undergraduate and then in my PhD programme at the University of Houston, where I focused on organic chemistry and nucleic acids chemistry. Because I was put into the highest tier, I was automatically mapped to the engineering track.

DNA 116
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Marquis Who’s Who Honors David R. Elmaleh, PhD, with Inclusion in Who’s Who in the World

The Pharma Data

A graduate of the Hebrew University of Jerusalem, he earned a Bachelor of Science in chemistry and physics and a Master of Science in physical organic chemistry before completing a Doctor of Philosophy in 1971. Marquis® publications may be visited at the official Marquis Who’s Who® website at www.marquiswhoswho.com. # # #.

article thumbnail

Marquis Who’s Who Honors James D. McChesney, PhD, with Inclusion in Who’s Who in the World

The Pharma Data

He continued his education at Indiana University, where he completed a Master of Arts in botany in 1964, and a Doctor of Philosophy in organic chemistry in 1965. He attributes his success to good fortune and hard work, and hopes to see some of his patented compounds gain approval and reach market readiness in the coming years.

article thumbnail

Empowering women in STEM: Navigating CMC regulatory affairs

Drug Target Review

Dr Lopa Bakrania brings over 18 years of experience in pharmaceutical process chemistry and CMC regulatory affairs. As Executive Director of CMC Regulatory Affairs at Biohaven , she leads efforts to develop innovative therapies from the clinic to market approval. When I joined, I was one of only five women on a team of 150 men.

Science 59